These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy. Hwang C; Sanda MG Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762 [TBL] [Abstract][Full Text] [Related]
3. Poxviruses as vectors for cancer immunotherapy. Kwak H; Hörig H; Kaufman HL Curr Opin Drug Discov Devel; 2003 Mar; 6(2):161-8. PubMed ID: 12669450 [TBL] [Abstract][Full Text] [Related]
4. Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors. Mastrangelo MJ; Lattime EC Cancer Gene Ther; 2002 Dec; 9(12):1013-21. PubMed ID: 12522440 [TBL] [Abstract][Full Text] [Related]
5. Pox viruses as eukaryotic cloning and expression vectors: future medical and veterinary vaccines. Taylor J; Paoletti E Prog Vet Microbiol Immunol; 1988; 4():197-217. PubMed ID: 3078866 [TBL] [Abstract][Full Text] [Related]
6. Poxvirus vaccines for cancer and HIV therapy. Essajee S; Kaufman HL Expert Opin Biol Ther; 2004 Apr; 4(4):575-88. PubMed ID: 15102606 [TBL] [Abstract][Full Text] [Related]
9. The potential role of fowlpox virus in rational vaccine design. Beukema EL; Brown MP; Hayball JD Expert Rev Vaccines; 2006 Aug; 5(4):565-77. PubMed ID: 16989636 [TBL] [Abstract][Full Text] [Related]
10. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Gómez CE; Nájera JL; Jiménez EP; Jiménez V; Wagner R; Graf M; Frachette MJ; Liljeström P; Pantaleo G; Esteban M Vaccine; 2007 Apr; 25(15):2863-85. PubMed ID: 17113200 [TBL] [Abstract][Full Text] [Related]
11. Viral vectors for gene transfer into antigen presenting cells. Monahan SJ; Salgaller ML Curr Opin Mol Ther; 1999 Oct; 1(5):558-64. PubMed ID: 11249662 [TBL] [Abstract][Full Text] [Related]
12. Biology and application of alphaviruses in gene therapy. Lundstrom K Gene Ther; 2005 Oct; 12 Suppl 1():S92-7. PubMed ID: 16231060 [TBL] [Abstract][Full Text] [Related]
13. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma. Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252 [TBL] [Abstract][Full Text] [Related]
18. Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens. Gómez CE; Nájera JL; Sánchez R; Jiménez V; Esteban M Vaccine; 2009 May; 27(24):3165-74. PubMed ID: 19446187 [TBL] [Abstract][Full Text] [Related]
20. Challenges and strategies: the immune responses in gene therapy. Zhou HS; Liu DP; Liang CC Med Res Rev; 2004 Nov; 24(6):748-61. PubMed ID: 15250039 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]